A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma

NCT06604715 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed or Refractory Multiple Myeloma

Interventions

DRUG: JNJ-87562761

Sponsor

Janssen Research & Development, LLC